$同源康医药-B(0_老虎社区_美港股上老虎

$同源康医药-B(02410)$ 公司重点布局的CDK抑制剂领域的三款药物（TYK-00540、TY-2699a、TY-302）的早期临床研究结果已在ESMO 2025年会上以壁报形式展示，获得国际学界关注

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":500987821006888,"tweetId":"500987821006888","gmtCreate":1763352051901,"gmtModify":1763352053840,"author":{"id":4184380269673420,"idStr":"4184380269673420","authorId":4184380269673420,"authorIdStr":"4184380269673420","name":"骏马飞驰吧","avatar":"https://static.tigerbbs.com/d3702f332c2e6980d8637b92198e2a1c","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":11,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 公司重点布局的CDK抑制剂领域的三款药物（TYK-00540、TY-2699a、TY-302）的早期临床研究结果已在ESMO 2025年会上以壁报形式展示，获得国际学界关注</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 公司重点布局的CDK抑制剂领域的三款药物（TYK-00540、TY-2699a、TY-302）的早期临床研究结果已在ESMO 2025年会上以壁报形式展示，获得国际学界关注</p></body></html>","text":"$同源康医药-B(02410)$ 公司重点布局的CDK抑制剂领域的三款药物（TYK-00540、TY-2699a、TY-302）的早期临床研究结果已在ESMO 2025年会上以壁报形式展示，获得国际学界关注","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/500987821006888","repostId":0,"isVote":1,"tweetType":1,"viewCount":107,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["02410"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":152,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}